

Preterm prelabour rupture of membranes (PPROM)

IMPORTANT: Consider individual clinical circumstances. Read the full disclaimer at www.health.qld.gov.au/qcg

Aspect	Consideration
Relevant to:	<ul style="list-style-type: none"> • Women with a live, singleton fetus with cephalic presentation between 22+0 and 36+6 weeks gestation with suspected prelabour rupture of membranes • Sub-categories of preterm variously defined by gestational age as¹: <ul style="list-style-type: none"> ○ Late preterm or near term (34+0 to 37+0 weeks) ○ Moderately preterm (32+0 to 33+6 weeks) ○ Very preterm (28+0 to 31+6 weeks) ○ Extremely preterm (less than 28+0 weeks)
Context	<ul style="list-style-type: none"> • Estimated: <ul style="list-style-type: none"> ○ Occurs in 3% of pregnancies² ○ Responsible for 30% of preterm births² ○ 25–50% will have an infection at presentation³ ○ 50% will go into labour within one week and 75% within two weeks⁴ • Advise women to present for assessment when PPRM is suspected
Aim of care	<ul style="list-style-type: none"> • Maximise benefits of increasing fetal maturity in-utero while minimising potential risks² <ul style="list-style-type: none"> ○ Care recommendations are therefore based on gestational age and individual maternal and fetal circumstances
Initial assessment	<ul style="list-style-type: none"> • Review history and time of fluid loss (sudden gush of fluid or continued leakage of fluid per vagina) • Conduct a clinical assessment [refer to Queensland Clinical Guideline: <i>Normal birth</i>⁵]: <ul style="list-style-type: none"> ○ Review of history (obstetric, social, medical, surgical) ○ Maternal vital signs ○ General physical examination ○ Abdominal palpation ○ FHR/CTG (relevant to gestation) ○ Assess vaginal loss on pad (amount, colour, consistency, odour, bleeding, meconium) ○ If unable to confirm diagnosis and/or repeat presentation with good history consider increased surveillance
Vaginal examination	<ul style="list-style-type: none"> • Avoid digital vaginal examination as may increase risk of infection^{6,7} • Sterile speculum <ul style="list-style-type: none"> ○ Visualise pooling of amniotic fluid or leakage from the cervical os with coughing ○ Visualise cervix, length, dilatation, exclude cord prolapse • If required, test vaginal secretions with immunoassay (e.g. AmniSure) or pH stick (e.g. Nitrazine) as per manufacturer's instructions
Investigations	<ul style="list-style-type: none"> • Routine antenatal bloods that are not already collected • Full blood count • Consider baseline C-reactive protein (CRP) <ul style="list-style-type: none"> ○ Conflicting evidence about usefulness in management of PPRM—may be a useful adjunct to exclude infection as has low sensitivity (less than 20%) and high specificity (greater than 90%) for chorioamnionitis⁸⁻¹⁰ • Dipstick urinalysis and midstream urine for microscopy, culture and sensitivity (MC&S) <ul style="list-style-type: none"> ○ Consider first void urinary PCR for gonorrhoea and chlamydia • Low vaginal and anal swab for Group B <i>Streptococcus</i> (GBS) • With sterile speculum: <ul style="list-style-type: none"> ○ High vaginal swab for MC&S • Transabdominal ultrasound scan to assess fetal wellbeing and confirm presentation

Initial management

Aspect	Considerations
Admission and inpatient care	<ul style="list-style-type: none"> • If confirmed PPROM, admit for initial assessment and monitoring as per local protocols • Maintain a high index of suspicion for: <ul style="list-style-type: none"> ○ Cord prolapse ○ Antepartum haemorrhage ○ Infection—suggested initial monitoring: <ul style="list-style-type: none"> ▪ Four hourly maternal heart rate, temperature, vaginal loss, uterine tenderness/activity, ask about fetal movements, FHR ▪ If greater than 28–30 weeks gestation, daily cardiotocograph • If chorioamnionitis suspected, recommend IV antibiotics—refer to Queensland Clinical Guideline: <i>Preterm labour and birth</i>¹¹ • Cerclage removal: optimal timing is unclear—removal versus retention showed no significant differences in prolonged latency, infection or neonatal outcomes^{12,13}
Routine antibiotics	<ul style="list-style-type: none"> • Known to prolong latency and reduce maternal and fetal infection following PPROM¹⁴ <ul style="list-style-type: none"> ○ No evidence that antibiotic prophylaxis alters perinatal mortality or longer-term outcomes • Optimal regimen is unclear¹⁵⁻¹⁷; recommend¹⁸: <ul style="list-style-type: none"> ○ Amoxicillin/ampicillin 2 g IV every 6 hours for 48 hours, followed by amoxicillin 250 mg oral every 8 hours for a total of 7 days (IV and oral) or until birth (whichever is sooner), PLUS erythromycin 250 mg oral every 6 hours for 7 days or until birth (whichever is sooner) ○ If penicillin allergy, erythromycin 250 mg oral 6 hourly for 10 days • Amoxicillin/clavulanic acid not recommended as associated with increased risk of necrotising enterocolitis¹⁴
Prematurity	<ul style="list-style-type: none"> • Refer to Queensland Clinical Guidelines: <i>Preterm labour and birth</i>¹¹, <i>Perinatal care at the threshold of viability</i>¹¹ and <i>Early onset Group B Streptococcus Disease</i>¹⁶ (EOGBSD) for: <ul style="list-style-type: none"> ○ Antenatal corticosteroids—routinely recommend before 35+0 weeks ○ Magnesium sulfate for neuroprotection (before 30 weeks gestation) ○ Care of gestations at the lower limits of viability ○ Intrapartum antibiotic prophylaxis for EOGBSD
Supportive care	<ul style="list-style-type: none"> • Counsel about prematurity relevant to gestation <ul style="list-style-type: none"> ○ Involve neonatologist/paediatrician in care planning • Offer psychological support • Involve other members of the multidisciplinary team relevant to circumstances (e.g. social worker, maternal fetal medicine specialist) • If less than 23+0 weeks gestation, counsel about viability and options for care
Self-care advice	<ul style="list-style-type: none"> • Advise about risk of cord prolapse and emergency management if occurs • Advise about the risk of infection and the importance of: <ul style="list-style-type: none"> ○ Personal hygiene—change sanitary pad four hourly (or more frequently), wiping front to back after toileting, showering in preference to baths ○ Self-monitoring temperature daily and vaginal loss with each pad change ○ Avoiding tampon use, vaginal creams/medications, vaginal intercourse, swimming/baths ○ Attending all review appointments • Advise to seek care from a health care professional if: <ul style="list-style-type: none"> ○ Concern about fetal movements [refer to Queensland Clinical Guideline: <i>Fetal movements</i>¹⁹] ○ Changes in vaginal loss (colour, odour, amount, new bleeding or meconium) ○ Signs of early labour/abdominal tenderness or pain ○ Temperature 37.5 °C or above ○ Feeling unwell or other concerns
In-utero transfer	<ul style="list-style-type: none"> • Consider the likelihood of preterm birth and need for transfer to higher level services • Tocolysis may be considered to achieve antenatal corticosteroid administration or in-utero transfer • If indicated, contact Retrieval Services Queensland (RSQ) to discuss and coordinate transfer ph:1300 799 127
Home care	<ul style="list-style-type: none"> • Consider individual circumstances when determining suitability for home care or other hospital supported accommodation (e.g. on or off hospital campus accommodation) <ul style="list-style-type: none"> ○ Insufficient evidence to compare planned home versus hospital management for serious neonatal morbidity, chorioamnionitis, gestational age at birth, birth weight or admission to neonatal intensive care²

Ongoing surveillance

There is a lack of high level evidence about optimal frequency or type of ongoing maternal and fetal surveillance. Local protocols may vary. The following *minimum* surveillance is based on the consensus view of the working party. Increase frequency, perform a clinical examination and seek medical review if there is concern for maternal or fetal wellbeing.

Suggested minimum surveillance

Surveillance	Frequency	Comment
Maternal self-monitoring		
Temperature	• Daily to twice daily	• Review, record at each presentation
Vaginal loss	• With pad changes	• Note change in colour, odour, amount, meconium, bleeding
Uterine tenderness/activity	• On-going	• May indicate preterm labour, chorioamnionitis
Fetal movements	• Note usual pattern and frequency of movement	• Medical review and cardiotocograph if changes
Maternal wellbeing	• On-going	• Further investigations as indicated
Fetal		
Cardiotocograph/FHR	• Weekly and with each presentation	• CTG as per local protocol—if no local protocol CTG if greater than 28–30 weeks • Fetal tachycardia may indicate infection ²⁰
Ultrasound scan	• Serial second weekly as indicated	• If greater than 23 weeks
Pathology		
Full blood count	• If indicated	• Limited evidence for detection of uterine infection and/or improving maternal and neonatal outcomes ¹⁵
Urine MC&S	• If indicated	
High/low vaginal swab	• If indicated	

Outcomes for planned birth versus expectant management (24–37 weeks gestation)

Any planned birth compared to expectant management		Risk with any planned birth
Antepartum haemorrhage ²¹	> 34 weeks (RR 0.6, 95% CI 0.4 to 0.9; 1 trial, n=1835)	Decreased
Chorioamnionitis ²²	> 34 weeks (RR 0.26; 95% CI 0.12 to 0.57; 3 trials, n=847)	Decreased
	< 34 weeks (RR 0.77; 95% CI 0.45 to 1.30; 4 trials, n=418)	No significant difference
Caesarean section ²²	> 34 weeks (RR 0.1.22; 95% CI 1.05 to 1.42; 5 trials, n=2922)	No significant difference
	< 34 weeks (RR 1.46; 95% CI 1.08 to 1.42; 5 trials, n=488)	No significant difference
Endometritis ²²	> 34 weeks (RR 0.37; 95% CI 0.10 to 1.4; 3 trials, n=2562)	No significant difference
	< 34 weeks (RR 2.23; 95% CI 1.29 to 3.84; 4 trials, n=418)	Decreased
Neonatal infection ²²	> 34 weeks (RR 0.93; 95% CI 0.66 to 1.30; 12 trials, n=3628)	No significant difference
	< 34 weeks (RR 1.61; 95% CI 0.74 to 3.50; 5 trials, n=490)	No significant difference
Respiratory distress ²¹	> 34 weeks (RR 1.6, 95% CI 1.1 to 2.30; n=1829)	Increased

Timing of birth

Optimal gestation at which to expedite birth is unclear.^{23,24}

Aspect	Considerations
Near term	• Between 34+0 and 36+6 weeks there is limited and inconsistent evidence to guide practice
Less than 34+0 weeks	• The risks of prematurity are generally greater than the risks of expectant management
Consider expediting birth	• If active labour establishes • If concern for maternal or fetal wellbeing at initial presentation or during subsequent care

References

1. World Health Organization. Born too soon: the global action report on preterm birth. [Internet]. 2012 [cited 2018 July 10]. Available from: <http://www.who.int>.
2. Abou El Senoun G, Dowswell T, HA M. Planned home versus hospital care for preterm prelabour rupture of membranes (PPROM) prior to 37 weeks' gestation. Cochrane Database of Systematic Reviews. [Internet]. 2014 [cited 2018 January 28]; (Issue 4. Art. No.: CD008053.) DOI:10.1002/14651858.CD008053.pub3.
3. Simhan HN, TP. C. Preterm premature rupture of membranes: diagnosis, evaluation and management strategies. British Journal of Obstetrics and Gynaecology 2005;112(1):32-7.
4. Goldenberg RL, Culhane JF, Iams JD, R. R. Epidemiology and causes of preterm birth. Lancet 2008;371(9606):75-84.
5. Queensland Clinical Guidelines. Normal birth. Guideline No. MN17.25-V3-R22. [Internet]. Queensland Health. 2017. [cited 2018 June 26]. Available from: <https://www.health.qld.gov.au/qcg>.
6. Alexander JM, Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. American Journal of Obstetrics and Gynecology 2000;183:1003-7.
7. Munson LA, Graham A, Koos BJ, GJ. V. Is there a need for digital examination in patients with spontaneous rupture of the membranes? American Journal of Obstetrics and Gynecology 1985;153:562-3.
8. Musilova I, Andrys C, Krejsek J, Drahosova M, Zednikova B, Pliskova L, et al. Amniotic fluid pentraxins: potential early markers for identifying intra-amniotic inflammatory complications in preterm pre-labor rupture of membranes. American Journal of Reproductive Immunology 2018;79(5):e12789-e.
9. Stepan M, Cobo T, Musilova I, Hornychova H, Jacobsson B, Kacerovsky M. Maternal serum c-reactive protein in women with preterm prelabour rupture of membranes. PLOS ONE 2016;11(3):e0150217.
10. Sung J-H, Choi S-J, Oh S-y, Roh C-R, Kim J-H. Revisiting the diagnostic criteria of clinical chorioamnionitis in preterm birth. BJOG: An International Journal of Obstetrics & Gynaecology 2017;124(5):775-83.
11. Queensland Clinical Guidelines. Perinatal care of the extremely preterm baby. Guideline No. MN20.32-V2-R25. [Internet]. Queensland Health. 2020. [cited 2022 April 20]. Available from: <https://www.health.qld.gov.au/qcg>.
12. Laskin MD, Yinon Y, WL. W. Preterm premature rupture of membranes in the presence of cerclage: is the risk for intra-uterine infection and adverse neonatal outcome increased? Journal of Maternal Fetal Neonatal Medicine 2012;25(4):424-8.
13. Giraldo-Isaza M, Berghella V. Cervical cerclage and preterm PROM. Clinical Obstetrics & Gynecology. 2011.;54(2).
14. Kenyon S, Boulvain M, JP N. Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews. 2013 [cited 2018 January 28]; Issue 12. Art. No.: CD001058. DOI:10.1002/14651858.CD001058.pub3.
15. Tita TN, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clinical Perinatology 2010;37(2):339-54.
16. Queensland Clinical Guidelines. Early onset Group B Streptococcal disease. Guideline No. MN16.20-V3-R21. [Internet]. Queensland Health. 2016. [cited 2018 January 15]. Available from: <https://www.health.qld.gov.au/qcg>.
17. Australasian Society for Infectious Diseases. Management of perinatal infections. [Internet]. 2014 [cited 28 February 2018].
18. Therapeutic Guidelines. Prophylaxis for preterm prelabour rupture of membranes. [Internet]. 2021 [cited 2022 April 11]. Available from: <https://tgldcdp.tg.org.au/>.
19. Queensland Clinical Guidelines. Fetal movements. Guideline No. MN18.46-V1-R23. [Internet]. Queensland Health. 2018. [cited 2018 October 23]. Available from: <https://www.health.qld.gov.au/qcg>.
20. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Term prelabour rupture of membranes (Term PROM). [Internet]. 2021 [cited 2022 April 20]. Available from: <https://www.ranzcog.edu.au/>.
21. Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet 2016;387(10017):444-52.
22. Bond D, Middleton P, Levett K, van der Ham D, Crowther C, Buchanan S, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews. [Internet]. 2017 [cited 2018 January 28]; (Issue 3. Art. No.: CD004735) DOI:10.1002/14651858.CD004735.pub4.
23. Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Systematic Reviews. [Internet]. 2010 [cited 2018 January 28]; (3):CD004735 DOI:10.1002/14651858.CD004735.pub3.
24. Quist-Nelson J, de Ruigh AA, Seidler AL, van der Ham DP, Willekes C, Berghella V, et al. Immediate delivery compared with expectant management in late preterm prelabour rupture of membranes: an individual participant data meta-analysis. Obstet Gynecol 2018;131(2):269-79.